Groundbreaking New Study Debunks Link Between Prenatal Paracetamol Use and Neurodevelopmental Disorders
For years, the safety of paracetamol (acetaminophen) use during pregnancy has been a hot topic of global debate, particularly since reports emerged suggesting a possible connection between prenatal exposure and neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD). A landmark study recently published in JAMA Internal Medicine has now provided the most robust and comprehensive evidence to date, firmly dispelling concerns that paracetamol intake during pregnancy elevates the risk of these conditions in offspring.
The international research consortium, led by the University of Hong Kong in collaboration with Aston University’s Professor Ian Chi-Kei Wong, analyzed data from an unprecedented cohort of over 700,000 mother-child pairs spanning more than two decades. Their research leveraged an innovative sibling-matched design to isolate the effects of paracetamol from confounding genetic and environmental variables. By comparing siblings from the same mother, where one sibling was exposed prenatally to paracetamol while the other was not, the study gained unparalleled precision in dissecting the true impact of the medication.
Paracetamol remains the most widely recommended analgesic and antipyretic for pregnant women worldwide due to its established safety profile and efficacy. However, public anxiety intensified following statements from US federal agencies implying a possible causal link between prenatal paracetamol use and increased risks for ASD or ADHD. Such assertions triggered a wave of scientific scrutiny and cautious reevaluation of analgesic protocols during gestation. Despite affirmations from global health authorities including the WHO regarding paracetamol’s safety, the evidence base had remained fragmented and inconclusive until this comprehensive investigation.
Researchers accessed and synthesized electronic medical records covering 708,020 mother-child pairs in Hong Kong between 2000 and 2023. Data encompassed detailed records of paracetamol exposure timing, dosage, and usage patterns throughout pregnancy trimesters, alongside longitudinal neurodevelopmental assessments of the children. The methodological rigor incorporated sibling-matched controls to minimize biases stemming from socio-economic, genetic predispositions, and familial environmental factors that often obscure causal inferences in epidemiological studies.
The results were unequivocal. The analysis revealed no statistically significant association between prenatal paracetamol exposure and elevated risks of ASD or ADHD in offspring. This absence of correlation persisted irrespective of how frequently or persistently the drug was used during pregnancy, as well as irrespective of whether exposure occurred during the first, second, or third trimester. These findings unequivocally contradict earlier concerns suggesting a dose-dependent or trimester-specific increased risk.
This study’s implications extend well beyond scientific circles, providing critical reassurance to millions of expectant mothers globally. Dr. Shan Luo, a research assistant professor involved in the study and a mother herself, emphasized the personal resonance of these findings. Having suffered herpes zoster during pregnancy, Dr. Luo refrained from using paracetamol due to prevailing apprehensions, underscoring how misinformation can impact health decisions and quality of life during critical periods. The study now empowers clinicians and patients alike to prioritize maternal comfort and safety without fear of adverse neurodevelopmental outcomes.
On a technical level, this research highlights the transformative power of big data analytics combined with innovative epidemiological study designs. Sibling-matched cohort analysis, a relatively novel approach in pharmacovigilance research, permits more accurate disentangling of mediator variables by controlling for latent genetic and shared environmental confounders. Utilizing Hong Kong’s extensive electronic medical records infrastructure enabled this granular, large-scale analysis with appropriate statistical models to ensure result validity and generalizability.
Professor Ian Wong, who holds the Regius Chair in Pharmacy at Aston University and is also a professor at the University of Hong Kong, underscored the pivotal role of interdisciplinary collaborations and international partnerships. By integrating pharmacological expertise with robust data science methodologies and clinical insights, the team addressed a globally urgent medication safety question with both speed and scientific rigor. The strategic alliance between Aston Pharmacy School and HKUMed’s Department of Pharmacology and Pharmacy serves as a model for future large-scale investigations in maternal and child health.
Importantly, the study calls attention to the nuanced communication required in public health messaging, especially concerning medication use in vulnerable populations. Erroneous or premature conclusions about drug risks can lead to suboptimal therapeutic decisions and unnecessary suffering. By furnishing definitive evidence on paracetamol’s safety during pregnancy, the research alleviates undue fears, reinforcing the notion that analgesic stewardship must be grounded in comprehensive data rather than anecdote or speculation.
Given the prominence of ASD and ADHD as key neurodevelopmental disorders impacting millions worldwide, elucidating environmental risk factors remains a top public health priority. This study’s methodical approach and robust data affirm that prenatal paracetamol does not contribute measurably to these conditions, thereby narrowing the focus onto other potential etiologies such as genetic susceptibilities, perinatal factors, and broader environmental exposures.
In conclusion, this seminal research provides a pivotal advance in our understanding of prenatal medication safety, rectifying misconceptions surrounding paracetamol use in pregnancy. It underscores that expectant mothers requiring analgesic interventions can do so with confidence, safeguarding both their well-being and that of their developing children. The publication offers a foundation for future pharmacoepidemiological studies utilizing sibling-matched designs to untangle complex drug safety questions impacting vulnerable populations.
For those interested in exploring the scientific details of this investigation, the full paper titled “Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or Attention-Deficit/Hyperactivity Disorder Among Sibling-Matched Cohorts” is accessible via JAMA Internal Medicine.
Subject of Research: People
Article Title: Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or Attention-Deficit/Hyperactivity Disorder Among Sibling-Matched Cohorts
News Publication Date: 29-Jun-2026
Web References: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2850975
References: DOI: 10.1001/jamainternmed.2026.2215
Keywords: Pregnancy, Human reproduction, Paracetamol, Acetaminophen, Autism spectrum disorder, ADHD, Neurodevelopmental disorders, Pharmacology, Drug safety, Sibling-matched cohort, Pharmacoepidemiology, Pain management during pregnancy
Tags: ADHD prenatal exposure studiesautism spectrum disorder risk factorsJAMA Internal Medicine paracetamol studylarge-scale pregnancy cohort researchmaternal paracetamol intake outcomesneurodevelopmental disorder risk assessmentparacetamol and neurodevelopmental disordersparacetamol pregnancy analgesic safetyprenatal drug exposure and child healthprenatal medication effects on child developmentprenatal paracetamol use safetysibling-matched cohort study
